GO:0060857 establishment of glial blood-brain barrier: Barrier Assembly, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060857 describes the biological process by which glial cells establish a tight barrier between blood and brain, preventing most molecules from entering the brain.
• The glial blood-brain barrier (BBB) is formed by tightly packed glial cells, and only lipid-soluble molecules or actively transported molecules can cross.
• Key molecular players include Mfsd2a, caveolin-1, Pdlim5, YAP/TAZ, angiopoietin-2, and glial growth factor 2, which regulate transcellular and paracellular permeability.
• Disruption of the glial BBB is linked to neurodegeneration, ischemic stroke, and Alzheimer's disease, making it a therapeutic target.
• Research models include BBB organoids, co-culture systems, and CRISPR-engineered cell models to study barrier integrity and permeability.
• Understanding GO:0060857 is essential for developing CNS drug delivery strategies and for modeling neurological disorders.
Description
The establishment of the glial blood-brain barrier (GO:0060857) is a critical biological process that forms a selective interface between the bloodstream and the brain, primarily mediated by glial cells. This barrier is essential for maintaining brain homeostasis by restricting the passage of most molecules, ions, and pathogens while allowing essential nutrients and lipid-soluble molecules to cross. In vertebrates, glial cells, such as astrocytes, play a central role in inducing and maintaining barrier properties in endothelial cells, but in some organisms, glial cells themselves form the barrier. The process is tightly regulated during development and remains dynamic in adulthood, responding to injury and disease. Researchers study GO:0060857 to understand neurovascular unit development, CNS drug delivery, and the pathogenesis of neurological disorders such as Alzheimer's disease and stroke. The glial BBB is not a static structure; it involves complex signaling between glial cells, pericytes, and endothelial cells, and its dysfunction is a hallmark of many brain pathologies.
establishment of glial blood-brain barrier At A Glance
| GO ID | GO:0060857 |
|---|---|
| GO term | establishment of glial blood-brain barrier |
| Ontology | biological_process |
| Synonym | establishment of glial BBB, establishment of glial blood/brain barrier |
| Major function | Formation of a selective barrier between blood and brain by glial cells, restricting paracellular and transcellular permeability |
| Key cell types | Glial cells (e.g., astrocytes), endothelial cells, pericytes |
| Major regulators | Mfsd2a, caveolin-1, Pdlim5, YAP/TAZ, angiopoietin-2, glial growth factor 2 |
| Associated diseases | Alzheimer's disease, ischemic stroke, neuroinflammation |
| Research models | BBB organoids, co-culture models, CRISPR-engineered cells |
What Is GO:0060857?
GO:0060857, establishment of glial blood-brain barrier, is defined as the biological process in which glial cells form a tight barrier between the blood and the brain. The glial cells pack tightly together, preventing most molecules from passing from the blood into the brain. Only lipid-soluble molecules or those that are actively transported can cross this barrier.
Why Is establishment of glial blood-brain barrier Important in Cell Biology?
Understanding the establishment of the glial blood-brain barrier is fundamental to neurobiology and medicine because this barrier controls the brain's microenvironment and protects it from harmful substances. Dysfunction of the glial BBB is implicated in a wide range of neurological disorders, including Alzheimer's disease, stroke, and neuroinflammation. Moreover, the barrier poses a major challenge for delivering therapeutics to the brain, as most drugs cannot cross it. Studying GO:0060857 helps researchers identify molecular targets to modulate barrier permeability for drug delivery and to develop therapies that restore barrier integrity in disease.
• Maintains brain homeostasis by regulating ion and nutrient balance.
• Protects the brain from toxins, pathogens, and peripheral immune cells.
• Dysfunction contributes to neurodegeneration, including Alzheimer's disease.
• Is a major obstacle for CNS drug delivery, requiring innovative strategies.
• Plays a role in ischemic stroke pathology and recovery.
• Involves glial cells, particularly astrocytes, which are key regulators of barrier properties.
• Molecular regulators such as Mfsd2a and caveolin-1 are potential therapeutic targets.
• Angiopoietin-2 exacerbates barrier dysfunction in Alzheimer's disease.
• Microglial polarization influences BBB integrity after stroke.
• Developmental studies reveal conserved mechanisms across species.
What Happens During establishment of glial blood-brain barrier?
Glial cell recruitment and specification
In simple terms: Glial cells, like astrocytes, are directed to the brain's blood vessels to start building the barrier.
During development, glial cells are recruited to the neurovascular unit, where they interact with endothelial cells and pericytes. This process involves signaling pathways that specify glial cell identity and promote their attachment to the vessel wall. In some organisms, glial cells themselves form the barrier, while in mammals, they induce barrier properties in endothelial cells.
Tight junction formation and paracellular sealing
In simple terms: Glial cells pack tightly together to seal the gaps between them, blocking most molecules from leaking through.
The establishment of the glial BBB requires the formation of tight junctions between glial cells or between glial cells and endothelial cells. This paracellular sealing is regulated by proteins such as Pdlim5, which modulates the YAP/TAZ pathway to control junctional integrity. Disruption of these junctions leads to increased permeability and barrier dysfunction.
Transcellular permeability regulation
In simple terms: The barrier also controls what enters cells through them, not just between them, using special transport mechanisms.
Transcellular permeability is regulated by proteins like Mfsd2a and caveolin-1. Mfsd2a inhibits caveolae-mediated transcytosis, thereby reducing the transport of molecules across the barrier. Glial growth factor 2 treatment has been shown to alleviate ischemia-reperfusion damage by decreasing Mfsd2a/caveolin-1-mediated transcellular permeability.
Molecular signaling and maintenance
In simple terms: Chemical signals from glial cells and other cells keep the barrier strong and functional.
Signaling molecules such as angiopoietin-2 and glial growth factor 2 modulate barrier integrity. Angiopoietin-2 promotes BBB dysfunction and neuroinflammation in Alzheimer's disease, while glial growth factor 2 alleviates damage through Mfsd2a/caveolin-1 and Pdlim5/YAP/TAZ pathways. These signals maintain the barrier under physiological conditions and are altered in disease.
Key Genes Involved in GO:0060857 establishment of glial blood-brain barrier
The following genes and proteins are key players in the establishment and regulation of the glial blood-brain barrier, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Mfsd2a | Inhibits caveolae-mediated transcytosis, reducing transcellular permeability | Target for modulating BBB permeability in stroke and drug delivery |
| Caveolin-1 | Mediates caveolae formation and transcytosis | Regulates transcellular transport; knockout models show altered BBB |
| Pdlim5 | Modulates YAP/TAZ pathway to control paracellular permeability | Potential target for tightening junctions after injury |
| YAP/TAZ | Transcriptional regulators of junctional integrity | Involved in mechanotransduction and barrier maintenance |
| Angiopoietin-2 | Promotes BBB dysfunction and neuroinflammation | Therapeutic target in Alzheimer's disease |
| Glial growth factor 2 | Alleviates ischemia-reperfusion damage to BBB | Protective factor in stroke models |
| Astrocyte markers (GFAP) | Structural support and barrier induction | Used to identify glial cells in BBB models |
| Pericyte markers (PDGFRβ) | Support barrier integrity and regulate blood flow | Co-culture models include pericytes for BBB formation |
| Endothelial tight junction proteins (Claudin-5, Occludin) | Form tight junctions to seal paracellular space | Assessed in permeability assays |
| ZO-1 | Scaffolding protein linking tight junctions to cytoskeleton | Marker of barrier integrity |
| P-glycoprotein | Efflux transporter at the BBB | Determines drug penetration into the brain |
| GLUT1 | Glucose transporter enriched at the BBB | Essential for brain energy supply; marker of BBB |
| LRP1 | Receptor for transcytosis of macromolecules | Target for drug delivery across BBB |
| Transferrin receptor | Mediates iron transport and transcytosis | Exploited for antibody-based brain delivery |
| Wnt/β-catenin signaling components | Regulate BBB development and maintenance | Genetic models reveal barrier formation defects |
| Sonic hedgehog (Shh) | Induces BBB properties in endothelial cells | Knockout models show barrier dysfunction |
| Retinoic acid signaling | Promotes BBB differentiation | Modulates barrier gene expression |
| Norrin | Activates Wnt signaling for BBB maintenance | Mutations linked to barrier defects |
How Is establishment of glial blood-brain barrier Regulated?
The establishment and maintenance of the glial blood-brain barrier are regulated by multiple signaling pathways. The Wnt/β-catenin pathway, activated by Norrin and other ligands, is crucial for BBB development and maintenance. Sonic hedgehog signaling from astrocytes induces barrier properties in endothelial cells. Additionally, angiopoietin-2 negatively regulates barrier integrity, and its inhibition can reduce neuroinflammation. Glial growth factor 2 treatment modulates Mfsd2a/caveolin-1 and Pdlim5/YAP/TAZ pathways to protect the barrier after ischemia-reperfusion injury. Microglial polarization also influences BBB integrity after stroke, with anti-inflammatory microglia promoting repair.
establishment of glial blood-brain barrier and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Angiopoietin-2 | Alzheimer's disease; promotes BBB dysfunction and neuroinflammation | Knockout or overexpression in mouse models; BBB organoids |
| Mfsd2a | Ischemic stroke; regulates transcellular permeability | Conditional knockout in endothelial cells; co-culture BBB models |
| Pdlim5 | Ischemic stroke; modulates paracellular permeability via YAP/TAZ | Knockdown or knockout in glial cells; permeability assays |
| Caveolin-1 | BBB dysfunction; mediates transcytosis | Knockout mice; in vitro BBB models |
| Glial growth factor 2 | Ischemic stroke; protective factor | Overexpression or treatment in stroke models |
Alzheimer's disease
In Alzheimer's disease, BBB dysfunction is an early event that contributes to neuroinflammation and cognitive decline. Angiopoietin-2 levels are elevated and promote BBB disruption and neuroinflammation, making it a potential therapeutic target. Neuroinflammation further exacerbates barrier damage, creating a vicious cycle.
Ischemic stroke
After ischemic stroke, the BBB is compromised, leading to edema and neuronal damage. Glial growth factor 2 treatment alleviates ischemia-reperfusion-damaged BBB integrity by decreasing Mfsd2a/caveolin-1-mediated transcellular and Pdlim5/YAP/TAZ-mediated paracellular permeability. Poliumoside, by modulating microglial polarization, also alleviates BBB disruption after stroke.
Neuroinflammation
Chronic neuroinflammation, driven by activated microglia and astrocytes, disrupts the glial BBB. In Alzheimer's disease, angiopoietin-2 aggravates barrier dysfunction and neuroinflammation. Targeting inflammatory pathways may help restore barrier integrity.
From establishment of glial blood-brain barrier-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate glial BBB permeability? | Knockout of gene X in glial cells or endothelial cells, followed by permeability assays |
| Does a point mutation in gene Y affect barrier integrity? | Point-mutation knock-in in cell lines or mice, assessed by TEER and tracer leakage |
| Can a tagged version of protein Z be used to track barrier formation? | Knock-in of fluorescent or epitope tag, imaging in organoids or co-cultures |
| Does overexpression of gene W strengthen the barrier? | Overexpression in glial cells or organoids, measure TEER and junctional proteins |
| What is the role of gene V in neuroinflammation-induced BBB disruption? | Knockout in microglia or astrocytes, co-culture with endothelial cells, cytokine profiling |
| Can CRISPR library screening identify novel BBB regulators? | Genome-wide knockout library in BBB organoids or co-culture, selection for barrier integrity |
How to Study the establishment of glial blood-brain barrier Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TEER measurement | Transendothelial electrical resistance, a proxy for barrier tightness | Assessing barrier integrity in co-culture models |
| Permeability assays | Flux of fluorescent tracers (e.g., FITC-dextran) across barrier | Evaluating drug penetration and barrier function |
| Immunofluorescence | Localization and expression of tight junction and glial markers | Visualizing barrier formation in vitro and in vivo |
| CRISPR knockout | Loss-of-function effects on barrier genes | Identifying causal genes in BBB establishment |
| CRISPR knock-in | Tagged or mutant protein expression | Tracking protein dynamics and function |
| RNA sequencing | Transcriptomic changes during barrier development | Discovering novel regulators and pathways |
| Proteomics | Protein abundance and modifications | Quantifying barrier-related proteins |
| Organoid culture | 3D BBB-like structures for permeability studies | Modeling human BBB for drug screening |
In vitro BBB models
Co-culture systems of endothelial cells with glial cells or pericytes are widely used to study glial BBB establishment. These models allow measurement of transendothelial electrical resistance (TEER) and permeability to tracers. BBB organoids derived from induced pluripotent stem cells provide a more physiologically relevant 3D model for investigating permeability of CNS therapeutics.
Genetic manipulation and screening
CRISPR-Cas9 knockout, point mutation, and knock-in approaches enable precise interrogation of genes involved in glial BBB establishment. Genome-wide CRISPR screens in BBB models can identify novel regulators of barrier integrity. Overexpression studies help assess gain-of-function effects on barrier properties.
Imaging and protein analysis
Immunofluorescence and confocal microscopy visualize tight junction proteins (e.g., Claudin-5, ZO-1) and glial markers (GFAP) in BBB models. Western blotting and proteomics quantify protein expression and post-translational modifications. Live-cell imaging with fluorescent tracers assesses barrier permeability in real time.
Transcriptomics and bioinformatics
RNA sequencing of glial cells and endothelial cells during BBB development reveals gene expression changes. Bioinformatics analyses, such as pathway enrichment and network analysis, identify key regulators and signaling cascades. Single-cell RNA sequencing can resolve heterogeneity in glial cell populations contributing to barrier formation.
How CRISPR Can Be Used to Study GO:0060857 establishment of glial blood-brain barrier
Knockout
CRISPR knockout of candidate genes in glial cells or endothelial cells is used to determine their necessity for glial BBB establishment. For example, knockout of Mfsd2a or Pdlim5 can reveal their roles in transcellular and paracellular permeability, respectively. Knockout models are validated by TEER and tracer leakage assays.
Point Mutation
Point mutations can mimic human disease variants or disrupt specific protein functions. For instance, mutating phosphorylation sites in Pdlim5 or YAP/TAZ can test their role in barrier regulation. These models help dissect signaling pathways without complete gene loss.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags allows real-time tracking of barrier proteins in live cells or organoids. Knock-in of disease-associated mutations provides models to study barrier dysfunction in a physiological context.
Overexpression
Overexpression of protective factors such as glial growth factor 2 or Mfsd2a can enhance barrier integrity and protect against ischemia-reperfusion injury. Overexpression models are useful for gain-of-function studies and therapeutic target validation.
How EDITGENE Supports establishment of glial blood-brain barrier Research
Researchers studying establishment of glial blood-brain barrier-related genes often need to determine whether a candidate gene is causally involved in barrier formation, maintenance, or dysfunction. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of genes identified from screens or patient data.
Contact EDITGENE today to design your custom CRISPR model for establishment of glial blood-brain barrier research.
Frequently Asked Questions About establishment of glial blood-brain barrier
What is GO:0060857 establishment of glial blood-brain barrier?
GO:0060857 is a biological process in which glial cells form a tight barrier between the blood and the brain, preventing most molecules from entering the brain.
What genes are involved in the establishment of the glial blood-brain barrier?
Key genes include Mfsd2a, caveolin-1, Pdlim5, YAP/TAZ, angiopoietin-2, and glial growth factor 2, among others.
How is the glial blood-brain barrier formed?
Glial cells pack tightly together and form tight junctions, regulated by signaling pathways such as Wnt/β-catenin and Sonic hedgehog.
What diseases are associated with glial blood-brain barrier dysfunction?
Alzheimer's disease, ischemic stroke, and neuroinflammation are linked to BBB disruption.
What models are used to study the glial blood-brain barrier?
In vitro co-culture models, BBB organoids, and CRISPR-engineered cells are commonly used.
How can CRISPR be used to study glial blood-brain barrier genes?
CRISPR knockout, knock-in, point mutation, and overexpression allow functional interrogation of candidate genes in barrier models.
What is the role of Mfsd2a in the blood-brain barrier?
Mfsd2a inhibits caveolae-mediated transcytosis, reducing transcellular permeability.
How does angiopoietin-2 affect the blood-brain barrier?
Angiopoietin-2 promotes BBB dysfunction and neuroinflammation, particularly in Alzheimer's disease.
Can the glial blood-brain barrier be repaired after injury?
Yes, factors like glial growth factor 2 have been shown to alleviate ischemia-reperfusion damage to the BBB.
What methods measure blood-brain barrier integrity?
TEER measurement, permeability assays with fluorescent tracers, and immunofluorescence for tight junction proteins are standard methods.
Conclusion
The establishment of the glial blood-brain barrier (GO:0060857) is a fundamental process that protects the brain and maintains its homeostasis. Dysregulation of this barrier contributes to major neurological disorders, and understanding its molecular mechanisms offers opportunities for therapeutic intervention. Advances in CRISPR-based models and organoid technology are accelerating research into barrier biology and drug delivery. EDITGENE provides comprehensive services to support these studies, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Zhao Z et al.. 2015. Establishment and Dysfunction of the Blood-Brain Barrier.. Cell 163(5):1064-1078 PMID: 26590417
- 2. Bergmann S et al.. 2018. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.. Nat Protoc 13(12):2827-2843 PMID: 30382243
- 3. Park JS et al.. 2023. Establishing Co-Culture Blood-Brain Barrier Models for Different Neurodegeneration Conditions to Understand Its Effect on BBB Integrity.. Int J Mol Sci 24(6) PMID: 36982361
- 4. Papelian S. 2026. Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease.. Int J Dev Neurosci 86(5):e70168 PMID: 42560134
- 5. Zhang XL et al.. 2024. Glial growth factor 2 treatment alleviates ischemia and reperfusion-damaged integrity of the blood-brain barrier through decreasing Mfsd2a/caveolin-1-mediated transcellular and Pdlim5/YAP/TAZ-mediated paracellular permeability.. Acta Pharmacol Sin 45(11):2241-2252 PMID: 38902501
- 6. Lee E et al.. 2026. Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation.. Cell Rep 45(1):116621 PMID: 41529684
- 7. Gao Y et al.. 2025. Poliumoside alleviates microglia-mediated inflammation and blood-brain barrier disruption via modulating the polarization of microglia after ischemic stroke in mice.. Phytomedicine 143:156881 PMID: 40446580
- 8. Gastfriend BD et al.. 2026. Development of the blood-brain barrier.. Development 153(2) PMID: 41574630
